Last reviewed · How we verify
NCT03150602
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
Phase 4 trial testing Pralatrexate in Peripheral T Cell Lymphoma in 22 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Taiwan Mundipharma Pharmaceuticals Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 30 August 2016 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Pralatrexate — full drug profile →
Conditions studied
- Peripheral T Cell Lymphoma — all drugs for Peripheral T Cell Lymphoma →
- Progression, Disease — all drugs for Progression, Disease →
Sponsor
Taiwan Mundipharma Pharmaceuticals Ltd. — full company profile →
Who can join
20 and older, any sex, with Peripheral T Cell Lymphoma or Progression, Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03150602
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pralatrexate
Trials testing the same drug.
- NCT07225985 — Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re · Phase 1, PHASE2 · not yet recruiting
- NCT07234162 — A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) · Phase 3 · recruiting
- NCT03240211 — Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL · Phase 1 · active not recruiting
- NCT04747236 — Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL · Phase 2 · recruiting
- NCT03598998 — Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas · Phase 1, PHASE2 · active not recruiting
Other recruiting trials for Peripheral T Cell Lymphoma
Currently open trials in the same condition.
- NCT07414758 — Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy · Phase 3 · recruiting
- NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
- NCT07389616 — A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell · Phase 2, PHASE3 · recruiting
- NCT07353840 — T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR · recruiting
- NCT07253129 — Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort · recruiting
Other Taiwan Mundipharma Pharmaceuticals Ltd. trials
Trials by the same sponsor.
- NCT04315831 — Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain · completed
- NCT03176121 — Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain · Phase 4 · completed
- NCT03176199 — A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in P · Phase 4 · completed
- NCT03155516 — Effect of Good Pain Management (GPM) Ward Program on Moderate to Severe Cancer Pain Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03150602 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taiwan Mundipharma Pharmaceuticals Ltd.
- Last refreshed: 12 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03150602.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing